Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crinetics Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crinetics Pharmaceuticals's regulatory disclosures and financial reporting.
Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of Common Stock in open-market transactions. The sales occurred on March 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, meaning the trades were scheduled in advance.
The transactions comprised 4,477 shares at a volume-weighted average price of $36.08 and 523 shares at a volume-weighted average price of $36.77, within disclosed intraday price ranges. Following these sales, he directly held 16,300 shares of Crinetics Pharmaceuticals common stock.
Crinetics Pharmaceuticals director Stephanie Okey reported an open-market sale of 3,000 shares of common stock at $39.67 per share on March 3, 2026. The trade was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2025, and she now holds 13,300 shares.
Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported an automatic sale of common stock tied to tax withholding. On the transaction date, 6,713 shares of common stock were sold in open-market transactions to cover his tax withholding obligation upon the vesting of restricted stock units granted on March 10, 2025.
The shares were sold pursuant to a pre-arranged Rule 10b5-1 trading plan, with a volume-weighted average price of $39.67 per share and a sale price range of $39.67 to $39.74 per share. After this tax-related sale, he directly held 78,121 shares of Crinetics common stock.
Crinetics Pharmaceuticals reported a change in its independent auditor. The Audit Committee dismissed BDO USA, P.C. as the company’s independent registered public accounting firm and stated that BDO’s reports on the 2024 and 2025 financial statements contained no adverse or qualified opinions.
The company reported no disagreements with BDO and no reportable events during those periods. The Audit Committee appointed PricewaterhouseCoopers LLP (PwC) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. BDO’s confirming letter to the SEC is filed as an exhibit.
Crinetics Pharmaceuticals, Inc. is an endocrine‑focused pharmaceutical company that has transitioned to commercial stage with PALSONIFY (paltusotine), its first FDA‑approved product. PALSONIFY was approved on September 25, 2025 as the first once‑daily oral somatostatin receptor ligand for adults with acromegaly who had an inadequate response to surgery or cannot undergo surgery.
The company is pursuing broader use of paltusotine, including a Phase 3 CAREFNDR trial in carcinoid syndrome and a European marketing application, where CHMP issued a positive opinion in February 2026. Crinetics is also advancing atumelnant, an oral ACTH antagonist in Phase 3 CALM‑CAH and pediatric BALANCE‑CAH studies for congenital adrenal hyperplasia, and preparing a seamless Phase 2/3 trial in ACTH‑dependent Cushing’s syndrome.
CRN09682, the first candidate from its nonpeptide drug conjugate platform for SST2‑positive tumors, entered a Phase 1/2 BRAVESST2 study after IND clearance in 2025. Crinetics holds a broad patent estate extending into the 2040s, partners selectively in Japan and certain technologies, and emphasizes rare endocrine diseases with significant unmet need.
Crinetics Pharmaceuticals reported fourth quarter and full year 2025 results marked by the U.S. launch of PALSONIFY for acromegaly and its first product revenue. Fourth quarter revenue was $6.2 million, including $5.4 million in net product revenue from PALSONIFY, with more than 200 enrollment forms and over 125 prescribing healthcare providers in the quarter.
For 2025, total revenue was $7.7 million, while research and development expenses reached $332.1 million and selling, general and administrative expenses were $191.3 million, leading to a net loss of $465.3 million. The company used $326.2 million of cash, below prior guidance, and ended 2025 with $1.0 billion in cash, cash equivalents and investment securities, rising to about $1.4 billion after a January 2026 equity offering that raised approximately $380 million in net proceeds.
Crinetics highlighted significant pipeline progress, including FDA approval of PALSONIFY in September 2025, a positive CHMP opinion in Europe, multiple pivotal trials for paltusotine and atumelnant, and the first clinical candidate from its nonpeptide drug conjugate platform. For 2026, the company guides to GAAP operating expenses of $600–650 million and non-GAAP operating expenses of $480–520 million, reflecting continued investment in commercialization and late-stage development.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported equity awards and updated his holdings. He received a stock option for 228,000 shares of Common Stock at an exercise price of $0.00, vesting in forty-eight equal monthly installments starting on February 23, 2026. He also received 62,000 restricted stock units, which vest 25% annually beginning on March 1, 2027. The filing also reflects indirect ownership of Common Stock through four family trusts and a spouse, with separate reported balances for each entity.